CRMD CorMedix Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Kaplan Myron	2. Issuer Name and Ticker or Trading Symbol CorMedix Inc. [ CRMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) C/O CORMEDIX INC., 300 CONNELL DRIVE,, SUITE 4200	3. Date of Earliest Transaction (MM/DD/YYYY) 5/17/2021
(Street) BERKELEY HEIGHTS, NJ 07922 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	5/17/2021		P		15000	A	$6.0318 (1)	165034	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$8.32							(2)	1/11/2031	Common Stock	30000		30000	D
Stock Option (Right to Buy Common Stock)	$5.63							(3)	2/25/2030	Common Stock	15000		15000	D
Stock Option (Right to Buy Common Stock)	$8.3							(4)	1/10/2029	Common Stock	15000		15000	D
Stock Option (Right to Buy Common Stock)	$2.85							(5)	2/16/2028	Common Stock	8000		8000	D
Stock Option (Right to Buy Common Stock)	$11.2							(6)	2/21/2027	Common Stock	8000		8000	D
Stock Option (Right to Buy Common Stock)	$21.4							(7)	4/28/2026	Common Stock	10000		10000	D

Explanation of Responses:
(1)	This transaction was executed in multiple trades at prices ranging from $5.98 to $6.09. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
(2)	These options were granted on 1/11/2021. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board.
(3)	These options were granted on 02/25/2020. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board.
(4)	These options were granted on 01/10/2019. These options are fully vested.
(5)	These options were granted on 02/16/2018. These options are fully vested.
(6)	These options were granted on 02/21/2017. These options are fully vested.
(7)	These options were granted on 4/28/2016. These options are fully vested.

Remarks: The Issuer effected a 1-for-5 reverse stock split of its common stock on March 26, 2019. All share and per share exercise price amounts shown in this Form 4 have been adjusted to reflect the reverse stock split.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Kaplan Myron C/O CORMEDIX INC., 300 CONNELL DRIVE, SUITE 4200 BERKELEY HEIGHTS, NJ 07922	X

Signatures
/s/ Myron Kaplan		5/19/2021
**Signature of Reporting Person		Date